Pay in 4 interest-free payments of $6.22 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Therefore, FOXO4-DRI shows potential as a keloid treatment to prevent the aggressiveness and relapse of keloids by alleviating the inflammatory microenvironment
The figure 25.3 % surpasses: Tirzepatide SURMOUNT-1: 22.5 % Semaglutide STEP-1: 14.9 % Retatrutide Phase 2: 24.2 % (comparable, but Phase 3 results for Retatrutide are still lacking) It raises the question whether CagriSema will be the first molecule with an effect truly comparable to bariatric surgery (typically 2530 % reduction)
What we are developing could be used as something like maintenance therapy where you could get subcutaneous injections every 3 to 6 months. The market opportunity also resulted in a dramatic legal battle between Pfizer and Novo Nordisk last year, when the two companies fought over buying Metsera, a start-up developing weight-loss drugs
For general maintenance or mild symptoms, once-daily dosing typically suffices and simplifies the protocol
Follow up with the rest of your routine
Healthy, radiant skin never stays the same
